(Q29038010)

3 August 2017

Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial (English)

2 references

https://doi.org/10.1016%2FS0140-6736%2806%2969558-5

27 March 2017

3 August 2017

1 reference

0 references

1 reference

1 reference

Ajay Vora

1

2 references

https://doi.org/10.1016%2FS0140-6736%2806%2969558-5

27 March 2017

3 August 2017

Chris D Mitchell

2

2 references

https://doi.org/10.1016%2FS0140-6736%2806%2969558-5

27 March 2017

3 August 2017

Lynne Lennard

3

2 references

https://doi.org/10.1016%2FS0140-6736%2806%2969558-5

27 March 2017

3 August 2017

TOB Eden

4

1 reference

https://doi.org/10.1016%2FS0140-6736%2806%2969558-5

27 March 2017

Sally E Kinsey

5

2 references

https://doi.org/10.1016%2FS0140-6736%2806%2969558-5

27 March 2017

3 August 2017

John Lilleyman

6

2 references

https://doi.org/10.1016%2FS0140-6736%2806%2969558-5

27 March 2017

3 August 2017

Sue M Richards

7

2 references

https://doi.org/10.1016%2FS0140-6736%2806%2969558-5

27 March 2017

3 August 2017

T O B Eden

4

1 reference

3 August 2017

Medical Research Council

8

1 reference

3 August 2017

National Cancer Research Network Childhood Leukaemia Working Party

9

1 reference

3 August 2017

language of work or name

English

0 references

publication date

October 2006

1 reference

https://doi.org/10.1016%2FS0140-6736%2806%2969558-5

27 March 2017

1 October 2006

1 reference

3 August 2017

2 references

https://doi.org/10.1016%2FS0140-6736%2806%2969558-5

27 March 2017

3 August 2017

368

2 references

https://doi.org/10.1016%2FS0140-6736%2806%2969558-5

27 March 2017

3 August 2017

9544

2 references

https://doi.org/10.1016%2FS0140-6736%2806%2969558-5

27 March 2017

3 August 2017

1339-1348

2 references

https://doi.org/10.1016%2FS0140-6736%2806%2969558-5

27 March 2017

Clinical pharmacology of oral thioguanine in acute myelogenous leukemia

3 August 2017

randomized experiment

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Clinical severe hepatic venoocclusive disease during induction treatment of acute monoblastic leukemia managed with defibrotide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Veno-occlusive disease of the liver in children following chemotherapy for acute myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Hepatic veno-occlusive disease caused by 6-thioguanine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Reversible hepatic veno-occlusive disease and 6-thioguanine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Peliosis hepatis induced by 6-thioguanine administration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Veno-occlusive disease of the liver associated with thiopurines in a child with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Veno-occlusive disease (VOD) in Crohn's disease (CD) treated with azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Veno-occlusive disease of the liver in children treated for Wilms tumor.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Veno-occlusive disease of the liver associated with chronic myelomonocytic leukemia treated with vincristine and standard doses of cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Hyperhomocysteinemia: an independent risk factor or a simple marker of vascular disease?. 1. Basic data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969558-5

7 January 2021

10.1016/S0140-6736(06)69558-5

Identifiers

DOI

2 references

https://doi.org/10.1016%2FS0140-6736%2806%2969558-5

27 March 2017

release_b33pdy62azecbokr4552tbwozi

3 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b33pdy62azecbokr4552tbwozi

24 November 2022

mapped directly with Wikidata item

1 reference